Researchers report that weight loss and diabetes medicines—commonly used under brand names including Mounjaro, Ozempic and Wegovy—are associated with an increased risk of hair loss. The findings are reported across outlets that describe the same class of drugs and highlight that the observed association comes from a study examining links between use of these medicines and hair loss outcomes. Both reports frame the results as evidence of a raised likelihood of hair loss rather than a definitive statement that the drugs directly cause it. The coverage focuses on the overall connection between treatment with these medicines and hair loss, noting that the drugs are widely prescribed for weight management and diabetes-related care. The studies’ key takeaway, as presented by the sources, is that people using these treatments may face an elevated risk of hair loss, prompting awareness and further investigation. The reports do not provide specific numbers, study size, or timeframes in the shared excerpts, and they do not describe differences among the individual medicines beyond mentioning them as examples within the same broader category.